Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

What's Happening In Bankruptcy Court This Coming Week No Photo Available

Yun Park

This coming week, bankruptcy judges will hear arguments regarding the Chapter 11 plans of the Catholic diocese in Syracuse, New York, ... (more story)

Quick Growth, Stiff Competition Led To Everstream's Ch. 11 No Photo Available

Emlyn Cameron

Everstream, a provider of fiber networks to businesses, was pushed into Chapter 11 by burdensome debt, disappointing returns on an agg... (more story)

Titans Of The Plaintiffs Bar: Philippe & Jennifer Selendy No Photo Available

Yun Park

Philippe and Jennifer Selendy, who met as associates at Cravath Swaine & Moore LLP and married in 1997, each spent nearly three decade... (more story)